FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019328052> ?p ?o ?g. }

• W2019328052 endingPage "171" @default.
• W2019328052 startingPage "163" @default.
• W2019328052 abstract "Background The effect of the addition of adjuvant chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma is unclear. We aimed to assess the contribution of adjuvant chemotherapy to concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone. Methods We did an open-label phase 3 multicentre randomised controlled trial at seven institutions in China. Randomisation was by a computer-generated random number code. Patients were stratified by treatment centre and randomly assigned in blocks of four. Treatment allocation was not masked. We randomly assigned patients with non-metastatic stage III or IV (except T3–4N0) nasopharyngeal carcinoma to receive concurrent chemoradiotherapy plus adjuvant chemotherapy or concurrent chemoradiotherapy alone. Patients in both groups received 40 mg/m2 cisplatin weekly up to 7 weeks, concurrently with radiotherapy. Radiotherapy was given as 2·0–2·27 Gy per fraction with five daily fractions per week for 6–7 weeks to a total dose of 66 Gy or greater to the primary tumour and 60–66 Gy to the involved neck area. The concurrent chemoradiotherapy plus adjuvant chemotherapy group subsequently received 80 mg/m2 adjuvant cisplatin and 800 mg/m2 per day fluorouracil for 120 h every 4 weeks for three cycles. Our primary endpoint was failure-free survival. We did efficacy analyses in our intention-to-treat population. Our trial is ongoing; in this report we present the 2 year survival results and acute toxic effects. This trial is registered with ClinicalTrials.gov, number NCT00677118. Findings 251 patients were assigned to the concurrent chemoradiotherapy plus adjuvant chemotherapy group and 257 to the concurrent chemoradiotherapy alone group. After a median follow-up of 37·8 months (range 1·3–61·0), the estimated 2 year failure-free survival rate was 86% (95% CI 81–90) in the concurrent chemoradiotherapy plus adjuvant chemotherapy group and 84% (78–88) in concurrent chemoradiotherapy only group (hazard ratio 0·74, 95% CI 0·49–1·10; p=0·13). Stomatitis was the most commonly reported grade 3 or 4 adverse event during both radiotherapy (76 of 249 patients in the concurrent chemoradiotherapy plus adjuvant chemotherapy group and 82 of 254 in the concurrent chemoradiotherapy alone group) and adjuvant chemotherapy (43 [21%] of 205 patients treated with adjuvant chemotherapy). Interpretation Adjuvant cisplatin and fluorouracil chemotherapy did not significantly improve failure-free survival after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma. Longer follow-up is needed to fully assess survival and late toxic effects, but such regimens should not, at present, be used outside well-designed clinical trials. Funding Sun Yat-sen University Clinical Research 5010 Programme (No 2007037), Science Foundation of Key Hospital Clinical Programme of Ministry of Health PR China (No 2010–178), and Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2010)." @default.
• W2019328052 created "2016-06-24" @default.
• W2019328052 creator A5010738468 @default.
• W2019328052 creator A5014930934 @default.
• W2019328052 creator A5018964484 @default.
• W2019328052 creator A5019191525 @default.
• W2019328052 creator A5021481437 @default.
• W2019328052 creator A5022919658 @default.
• W2019328052 creator A5027566521 @default.
• W2019328052 creator A5028689142 @default.
• W2019328052 creator A5032656037 @default.
• W2019328052 creator A5038326454 @default.
• W2019328052 creator A5038488987 @default.
• W2019328052 creator A5051005965 @default.
• W2019328052 creator A5054098933 @default.
• W2019328052 creator A5057134732 @default.
• W2019328052 creator A5080448292 @default.
• W2019328052 creator A5083147929 @default.
• W2019328052 creator A5084486984 @default.
• W2019328052 creator A5085271871 @default.
• W2019328052 creator A5085462851 @default.
• W2019328052 creator A5086231114 @default.
• W2019328052 creator A5088883924 @default.
• W2019328052 creator A5089420346 @default.
• W2019328052 date "2012-02-01" @default.
• W2019328052 modified "2023-10-09" @default.
• W2019328052 title "Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial" @default.
• W2019328052 cites W1544199867 @default.
• W2019328052 cites W1916546429 @default.
• W2019328052 cites W1968017437 @default.
• W2019328052 cites W1969762178 @default.
• W2019328052 cites W1976270947 @default.
• W2019328052 cites W1992300472 @default.
• W2019328052 cites W1992689224 @default.
• W2019328052 cites W2014401523 @default.
• W2019328052 cites W2019419382 @default.
• W2019328052 cites W2043945205 @default.
• W2019328052 cites W2075324122 @default.
• W2019328052 cites W2082933047 @default.
• W2019328052 cites W2086931150 @default.
• W2019328052 cites W2106787323 @default.
• W2019328052 cites W2109261874 @default.
• W2019328052 cites W2112497607 @default.
• W2019328052 cites W2116297115 @default.
• W2019328052 cites W2120308976 @default.
• W2019328052 cites W2125919881 @default.
• W2019328052 cites W2126919372 @default.
• W2019328052 cites W2139248078 @default.
• W2019328052 cites W2146505874 @default.
• W2019328052 cites W2148593237 @default.
• W2019328052 cites W2148900467 @default.
• W2019328052 cites W2151645021 @default.
• W2019328052 cites W2158776902 @default.
• W2019328052 cites W2160982012 @default.
• W2019328052 doi "https://doi.org/10.1016/s1470-2045(11)70320-5" @default.
• W2019328052 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22154591" @default.
• W2019328052 hasPublicationYear "2012" @default.
• W2019328052 type Work @default.
• W2019328052 sameAs 2019328052 @default.
• W2019328052 citedByCount "439" @default.
• W2019328052 countsByYear W20193280522012 @default.
• W2019328052 countsByYear W20193280522013 @default.
• W2019328052 countsByYear W20193280522014 @default.
• W2019328052 countsByYear W20193280522015 @default.
• W2019328052 countsByYear W20193280522016 @default.
• W2019328052 countsByYear W20193280522017 @default.
• W2019328052 countsByYear W20193280522018 @default.
• W2019328052 countsByYear W20193280522019 @default.
• W2019328052 countsByYear W20193280522020 @default.
• W2019328052 countsByYear W20193280522021 @default.
• W2019328052 countsByYear W20193280522022 @default.
• W2019328052 countsByYear W20193280522023 @default.
• W2019328052 crossrefType "journal-article" @default.
• W2019328052 hasAuthorship W2019328052A5010738468 @default.
• W2019328052 hasAuthorship W2019328052A5014930934 @default.
• W2019328052 hasAuthorship W2019328052A5018964484 @default.
• W2019328052 hasAuthorship W2019328052A5019191525 @default.
• W2019328052 hasAuthorship W2019328052A5021481437 @default.
• W2019328052 hasAuthorship W2019328052A5022919658 @default.
• W2019328052 hasAuthorship W2019328052A5027566521 @default.
• W2019328052 hasAuthorship W2019328052A5028689142 @default.
• W2019328052 hasAuthorship W2019328052A5032656037 @default.
• W2019328052 hasAuthorship W2019328052A5038326454 @default.
• W2019328052 hasAuthorship W2019328052A5038488987 @default.
• W2019328052 hasAuthorship W2019328052A5051005965 @default.
• W2019328052 hasAuthorship W2019328052A5054098933 @default.
• W2019328052 hasAuthorship W2019328052A5057134732 @default.
• W2019328052 hasAuthorship W2019328052A5080448292 @default.
• W2019328052 hasAuthorship W2019328052A5083147929 @default.
• W2019328052 hasAuthorship W2019328052A5084486984 @default.
• W2019328052 hasAuthorship W2019328052A5085271871 @default.
• W2019328052 hasAuthorship W2019328052A5085462851 @default.
• W2019328052 hasAuthorship W2019328052A5086231114 @default.
• W2019328052 hasAuthorship W2019328052A5088883924 @default.
• W2019328052 hasAuthorship W2019328052A5089420346 @default.
• W2019328052 hasConcept C126322002 @default.
• W2019328052 hasConcept C141071460 @default.
• W2019328052 hasConcept C143998085 @default.

• next